{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026739","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.960316+00:00","generated_at":"2026-06-21T03:01:21.331388+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma elects James Flynn to Board; annual meeting results","bullets":["James Flynn elected to Board for term ending 2025 under cooperation agreement with Cable Car Capital.","Flynn granted option to purchase 12,000 shares at $2.32; other directors each granted 6,000-share options.","Stockholders elected Grais, Hove, Flynn; ratified KPMG as auditor; approved executive compensation.","Board is evaluating strategic options for the company, per press release."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026739","json":"https://secwatch.observer/filing/0000950170-22-026739.json","markdown":"https://secwatch.observer/filing/0000950170-22-026739.md","text":"https://secwatch.observer/filing/0000950170-22-026739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/abio-20221215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:01:21.331388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"472b34c97b","claim":"James Flynn was elected as director at Oruka Therapeutics, Inc..","evidence_excerpt":"On December 15, 2022, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) elected James Flynn, as a director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"b83397a62c3f81517c606ff7f95d33cdfd477790","claim":"Oruka Therapeutics, Inc. shareholders approved Election of Directors at the 2022-12-15 meeting.","evidence_excerpt":"1. Election of Directors: Nominee For Withheld Broker Non-Votes Dr. Linda Grais 5,625,386 192,401 3,296,871 Dr. Anders Hove 5,331,324 486,463 3,296,871 Mr. James Flynn 5,616,593 201,194 3,296,871","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-15"}],"fact_type":"shareholder_vote"},{"claim_id":"dc58edeabc6b6341d7096c1dd601418ad6a8a3d8","claim":"Oruka Therapeutics, Inc. shareholders approved Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-12-15 meeting.","evidence_excerpt":"2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Abstentions Broker Non-Votes 8,980,366 116,906 17,386 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-15"}],"fact_type":"shareholder_vote"},{"claim_id":"f9b0e67255ad7f795e24d176464c1c43b3afb39f","claim":"Oruka Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2022-12-15 meeting.","evidence_excerpt":"3. Executive Compensation: For Against Abstentions Broker Non-Votes 5,301,245 456,787 59,755 3,296,871","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017022026739/0000950170-22-026739-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-12-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}